Tevogen Bio: The Next Frontier of Medicine

Name: Tevogen Bio: The Next Frontier of Medicine
Uploaded: 2024-07-09T11:37:33-0400
Duration: PTHMS
Description: Dr. Neal Flomenberg, Chief Scientific Officer, and Dr. Lori Grosso, Clinical Development Lead, Tevogen Bio (NSDQ: TVGN), sit down with Nasdaq's Kristina Ayanian to discuss how the clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.

Published

Jul 9, 2024 11:37AM EDT

Live From MarketSite 2025

About This Series With Kristina Ayanian

Nasdaq Listings Host Kristina Ayanian delves into companies' notable accomplishments, industry trends, and the driving factors behind their success through engaging conversations with C-suite executives and industry leaders.

Dr. Neal Flomenberg, Chief Scientific Officer, and Dr. Lori Grosso, Clinical Development Lead, Tevogen Bio (NSDQ: TVGN), sit down with Nasdaq's Kristina Ayanian to discuss how the clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.

Transcripts

No transcript available